Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 13th Street, Charlestown, Boston, MA, 02129, USA.
Department of Medicine and Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Probiotics Antimicrob Proteins. 2022 Aug;14(4):699-711. doi: 10.1007/s12602-022-09938-0. Epub 2022 Apr 26.
To evaluate the influence of oral probiotic Bifidobacterium animalis subsp. lactis (BL-11) supplementation on salivary microbiota composition and the association with growth parameters, and behavioral symptoms in individuals with Prader-Willi syndrome (PWS). In this post hoc analysis, we included a subset of 36 PWS patients with available saliva samples from our original randomized, double-blinded, placebo-controlled trial (Chinese Clinical Trial Registry, ChiCTR1900022646, April 20, 2019). Among the 36 subjects, 17 subjects were allocated to the probiotic group for daily use of the BL-11 probiotic and 19 subjects were allocated to the placebo group. Groupwise and longitudinal differences in salivary microbiota abundances, biodiversity metrics, and height were analyzed. Linear correlations were found between identified differentially abundant salivary microbiota and clinical parameters. Salivary microbiome α-diversity was found to be higher in the probiotic-treated group at week 12 relative to placebo controls (P < 0.05). Leptotrichia, Paracoccus, and Faecalibacterium were found to be more abundant in the probiotic-treated group (P < 0.05). Salivary microbiota abundance and predicted functional profiling abundance correlations were found to be associated with anti-inflammation, anti-obesity, toxin degradation, and anti-oxidative injury effects (Q < 0.1). Several oral taxa also displayed correlations with social behavior severity scores in the probiotic-treated group (Q < 0.1). The findings suggest novel salivary microbiota compositional changes in response to the oral supplementation of BL-11 probiotic in individuals with PWS. The observed differentially abundant taxa between groups post-treatment were highly correlated with interventional effects on growth and social behaviors, although further investigation is warranted. Clinical Trial Registration The original clinical trial was registered under the Chinese Clinical Trial Registry with registration number ChiCTR1900022646 (April 20, 2019).
评估口服益生菌双歧杆菌乳亚种（BL-11）补充对普拉德-威利综合征（PWS）个体唾液微生物群落组成的影响及其与生长参数和行为症状的关系。在这项事后分析中，我们纳入了来自我们原始随机、双盲、安慰剂对照试验（中国临床试验注册中心，ChiCTR1900022646，2019 年 4 月 20 日）的 36 名 PWS 患者中有可用唾液样本的亚组。在 36 名受试者中，17 名受试者被分配到益生菌组，每天使用 BL-11 益生菌，19 名受试者被分配到安慰剂组。分析了唾液微生物群落丰度、生物多样性指标和身高的组间和纵向差异。发现鉴定的差异丰度唾液微生物群落与临床参数之间存在线性相关性。与安慰剂对照组相比，益生菌治疗组在第 12 周时唾液微生物组α多样性更高（P<0.05）。在益生菌治疗组中，发现 Leptotrichia、Paracoccus 和 Faecalibacterium 更为丰富（P<0.05）。发现唾液微生物群落丰度和预测功能谱丰度相关性与抗炎、抗肥胖、毒素降解和抗氧化损伤作用相关（Q<0.1）。在益生菌治疗组中，几个口腔分类群也与社会行为严重程度评分相关（Q<0.1）。研究结果表明，PWS 个体口服 BL-11 益生菌补充后，唾液微生物群落组成发生了新的变化。治疗后组间观察到的差异丰度分类群与生长和社会行为的干预效应高度相关，尽管需要进一步研究。临床试验注册 原始临床试验在中国临床试验注册中心注册，注册号为 ChiCTR1900022646（2019 年 4 月 20 日）。
